Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Upgraded at Wall Street Zen

Posted by Geri Gentry on Nov 11th, 2026

Wall Street Zen upgraded shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Free Report) from a sell rating to a hold rating in a research note published on Sunday morning,Wall Street Zen reports.

A number of other research analysts also recently commented on DMRA. Weiss Ratings restated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, September 14th. TD Cowen raised Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research report on Monday, August 24th. Guggenheim began coverage on Damora Therapeutics, Inc. Common Stock in a research note on Friday, November 6th. They set a “buy” rating and a $59.00 price target for the company. Jefferies Financial Group assumed coverage on Damora Therapeutics, Inc. Common Stock in a research note on Monday, July 27th. They set a “buy” rating and a $50.00 price target for the company. Finally, Wedbush reiterated an “outperform” rating and set a $40.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, September 29th. Three analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $46.38.

Get Our Latest Stock Report on DMRA

Damora Therapeutics, Inc. Common Stock Stock Up 0.3%

Shares of NASDAQ:DMRA opened at $24.15 on Friday. The firm has a fifty day moving average of $22.54 and a two-hundred day moving average of $25.65. The firm has a market capitalization of $1.49 billion, a P/E ratio of -7.17 and a beta of 1.52. Damora Therapeutics, Inc. Common Stock has a 12-month low of $15.00 and a 12-month high of $38.33.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.12. Equities research analysts expect that Damora Therapeutics, Inc. Common Stock will post -2.09 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Jennifer Jarrett bought 12,500 shares of the firm’s stock in a transaction on Friday, September 25th. The stock was purchased at an average price of $20.23 per share, with a total value of $252,875.00. Following the completion of the transaction, the chief executive officer directly owned 512,500 shares of the company’s stock, valued at $10,367,875. This trade represents a 2.50% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.40% of the company’s stock.

Hedge Funds Weigh In On Damora Therapeutics, Inc. Common Stock

A number of institutional investors have recently modified their holdings of the company. Braidwell LP acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock in the second quarter worth $42,146,000. Seven Fleet Capital Management LP acquired a new position in Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at $7,398,000. Squarepoint Ops LLC acquired a new position in Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at $303,000. Finally, Arizona State Retirement System acquired a new position in Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at $260,000. Institutional investors own 14.20% of the company’s stock.

About Damora Therapeutics, Inc. Common Stock

(Get Free Report)

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.